Nov 18 2020 - 12:36
Back

Pfizer ends COVID-19 trial with 95% efficacy

Pfizer Inc said on Wednesday that final results from the late-stage trial Lebanon, news ,lbci ,أخبار Vaccine, Coronavirus, Covid-19,Pfizer,Pfizer Inc said on Wednesday that final results from the late-stage trial
episodes
Pfizer ends COVID-19 trial with 95% efficacy
Lebanon News
Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.
advertisement

MARKET REACTION: Equity markets strengthened slightly on the news. Europe's STOXX 600 and U.S. S&P 500 e-mini futures both hit session highs. However, the moves were small compared to the jump after Pfizer's previous announcement. The reaction in European government bonds and in currencies was muted.

Pfizer shares were 2.6% higher in U.S. morning trade at $36.98 and U.S.-listed shares of partner BioNTech SE were up 3% at $89.61.
 
 
REUTERS
advertisement
Read also